MASS X PLUS
144.90 $
144.90 $
20
LGD4033
10
RAD140
20
MK677
**These statements have not been evaluated by the Food and Drug
administration (FDA). This product is not intended to diagnose, treat,
cure, or prevent any disease.
*All amounts per 1Ml serving
LGD 4033 is a SARM that is more commonly known by the name Ligandrol but has also been called VK5211 or Anabolicum. In various animal studies, LGD 4033 has been shown to increase anabolic activity in the muscles and have positive effects on bone density in male rats experiencing hypogonadism, and have success treating female postmenopausal rats experiencing osteoporosis.
Additionally, various studies presented at the 62nd Annual Meeting of the Gerontology Society of America, found that use with LGD 4033 in animals increased resistance to fracture and bone mineral density after 12 weeks. This increase was noted in cancellous bone after a dose of 0.3 mg/kg per day and noted in cortical bone after a dose of 0.03 mg/kg per day (https://www.sec.gov/Archives/edgar/data/886163/000119312509239917/d425.htm). Furthermore, in both hypogonadal rats and normal rats LGD 4033 use was seen to increase skeletal muscle mass and muscle fiber diameter correlating to contractile power of the muscle which indicates greater muscle strength. In a fascinating study conducted by Roch et. Al, 3-month-old Sprauge-Dawley rats were ovariectomized and given LGD 4033 for 5 weeks. Each rat in the experimental groups was given doses of either 0.04, 0.4 or 4 mg/kg of body weight/day. After use, the researchers conducted an analysis of fiber size, capillary density, and various enzyme levels, additionally, the uterus, gastrocnemius, and soleus muscles were all weighed to document any changes before and after use (https://www.frontiersin.org/articles/10.3389/fendo.2020.556581/full#B30). When determining the effects of the LGD 4033 on the rats, researchers took samples from the quadriceps femoris muscle in order to determine changes in intramuscular fat content. In addition to determining changes in the intramuscular fat content, it was found that with treatment with LGD 4033 there was higher capillary density. Furthermore, with LGD 4033, there was higher activity of the enzyme citrate synthase in the gastrocnemius muscle. It was also found that after testing, the activity of the enzyme lactate dehydrogenase was higher in the longissimus muscle (https://www.frontiersin.org/articles/10.3389/fendo.2020.556581/full#B30). Overall, animal research with LGD 4033 had a uterotrophic effect when subjects were given a 4 mg dosage, beneficial effects on muscle vascularization as well as muscle metabolism were also found following use. Additionally, after the 4 mg dosage of LGD 4033, researchers reported increased muscular weight and increased weight of intramuscular fat content.
RAD 140 SARM, or (2-chloro-4-[[(1R,2S)-1-[5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl]-2-hydroxypropyl]amino]-3-methylbenzonitrile, also known as testolone was originally synthesized for Radius Health Inc. in conjunction with researchers from the University of Illinois, Obiter Research, and Cambridge Major Laboratories. Per the initial paper detailing the synthesis and preliminary findings of the compound, RAD140 has the stability to (t1/2 >2 h) in incubations with rat and monkey microsomes, as well as a high affinity for the androgen receptor (Ki = 7 nM), approximately 4 times the affinity than that of testosterone itself. At the same time, the nearest hormone receptor activated by RAD140 was progesterone at a level of 750nM. The earliest primate studies on RAD-140 indicated that even at the lowest dose range 0.1mg/kg, juvenile macaques gained a mean of ten percent in body weight, during the 28-day trial period, which was primarily confirmed to be lean body mass via DEXA scans performed before and after the trial period, however, this was somewhat variable.
In a study conducted by Jayaraman et. Al, gonadectomized, male rats were studied to see the effects supplementation with RAD 140 had in regards to neuroprotection in order to make conclusions regarding the usefulness of SARMs against neurodegenerative disorders. The rats were orally provided with 1 mg/kg a day of RAD 140 for 2 weeks. It was found that RAD140 was able to reduce apoptosis caused by Aᵝ, apoptosis activator II, and hydrogen peroxide by a significant amount. This is due to the role MAPK signaling plays in neuroprotection. Aᵝ was by far the most potent of the apoptosis insults introduced to the rats. After 24 hours of exposure to Aᵝ, 50% of viable neurons in the rats had decreased, however, when given RAD 140 in a concentration-dependent matter, the viability of the neurons had increased exponentially. The most effective concentration of RAD 140 was 100 nM, which led to approximately 90% neuron survival after Aᵝ exposure Study. In addition to measuring the neuroprotection against various apoptosis insults, researchers also measured the effects RAD 140 had on kainate-induced neuron death. It was found that when compared to treatment with a vehicle, kainate-induced neuron death was significantly reduced Study.